Leaders across industry and health authorities agree that finding answers to market access are critical to the future of delivering breakthrough medicines to patients. Unfortunately, policies and practice do not always marry up. This meeting is the starting point to engage professionals working with value and regulatory strategies. HTA bodies and regulators are breaking down silos, facilitating access to new medicines and increasing efficiencies in assessment processes. R&D process will need to be able to generate evidence for registration and reimbursement. Bringing together the policy makers and the policy implementers, to keep you ahead of the game of practical solutions.